logo
logo
SRDX stock ticker logo

Surmodics, Inc.

NASDAQ•SRDX
執行長: Mr. Gary R. Maharaj
板塊: Healthcare
行業: Medical - Devices
上市日期: 1998-03-04
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
聯絡資訊
9924 West 74th Street, Eden Prairie, MN, 55344-3523, United States
952-500-7000
www.surmodics.com
市值
$614.51M
本益比 (TTM)
-43.3
23.6
股息率
--
52周最高
$43.00
52周最低
$25.87
52周範圍
100%
排名49Top 66.7%
3.2
F-Score
改良版 Piotroski 分析
基於 10 年期基本面
疲弱 • 3.2 / 9 分
評分區間 (0-9)
8-9: 價值優異
6-7: 基本面強勁
4-5: 整體穩健
0-3: 表現疲弱
資料區間: 2016-2025

財務儀表板

Q3 2025 數據

營業收入

$29.57M-2.55%
近4季度走勢

每股收益

-$0.37-30.19%
近4季度走勢

自由現金流

$904.00K-130.21%
近4季度走勢

2025 Q3 財報亮點

核心亮點

Nine Month Revenue Decline Nine month total revenue $87.6M, reflecting a 6% decrease from prior period levels.
Net Loss Widens Significantly Net loss reached $(14.2M) for nine months, significantly wider than prior year's $(8.1M).
Medical Device Sales Drop Medical Device product sales $27.4M, down 19% driven by SurVeil DCB shipment decrease.
Merger Charges Inflate SG&A SG&A expense increased 14% to $48.0M, primarily due to $10.1M in merger-related charges.

關注風險

SurVeil DCB Revenue Forecast SurVeil DCB revenue forecast decline of $7.5M in fiscal 2025, offsetting Pounce platform growth.
FTC Merger Litigation Risk Consummation of pending acquisition remains subject to resolution of FTC litigation proceedings.
Recent Cyber Security Incident Experienced June 2025 cyber incident; incurred $1.9M response costs with ongoing reputation risks.
Product Gross Margin Pressure Product gross margin compressed 460 basis points to 50.7% due to SurVeil under-absorption issues.

未來展望

2025 Liquidity Sufficiency Existing cash ($32.7M) and credit facility expected to fund 2025 operations and capital expenditures.
Continued Gross Profit Decline Product gross profit and margin expected to decline further due to SurVeil DCB revenue decline.
High Near-Term Expenses SG&A and R&D expenses remain significant, driven by merger charges and Pounce/Sublime platform investment.
Future Financing Potential Long-term cash needs depend on commercialization success; may seek debt or equity financing later.

同行對比

營業收入 (TTM)

CCRN stock ticker logoCCRN
$1.05B
-21.6%
VREX stock ticker logoVREX
$854.40M
+4.1%
BVS stock ticker logoBVS
$568.09M
-0.9%

毛利率 (最新季度)

XOMA stock ticker logoXOMA
93.6%
-9.4pp
SMLR stock ticker logoSMLR
91.5%
+0.1pp
DCTH stock ticker logoDCTH
85.5%
+1.9pp

關鍵指標

股票代碼
市值
本益比 (TTM)
股東權益報酬率 (TTM)
負債率
BVS$667.62M29.013.8%45.5%
SRDX$614.51M-43.3-12.8%19.2%
TCMD$570.13M29.49.3%5.8%

長期趨勢

近4季度
營業收入
淨利
營運現金流
4季度營業收入複合增長率
-3.8%
基本持平
4季度淨利複合增長率
N/M
盈利狀態轉變
現金流穩定性
75%
現金流波動較大

深度研究

下次財報:2026年4月28日
|
每股收益:-
|
營業收入:-
財務數據
電話會議
財務報告
新聞
損益表
資產負債表
現金流量表
財務比率
變化率
損益表
過去12個月
無資料